EG 011

Drug Profile

EG 011

Alternative Names: Ad-VEGF-D; EG011; VEGF-D short-form

Latest Information Update: 23 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies; Ischaemic heart disorder therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor D stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 08 Nov 2012 Discontinued - Phase-I/II for Angina pectoris in Finland (Intracoronary)
  • 16 May 2012 Ark Therapeutics completes the phase I portion of its phase I/IIa trial in Angina pectoris in Finland
  • 25 Aug 2011 EG 011 is available for partnering as of 25 Aug 2011. www.arktherapeutics.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top